Much of it was already announced during the quarter, especially the big contracts, but still a nice quarterly result from ALC! Following points to add from Kate’s comments in the call:
- Seeing signs in the UK bids that US healthcare companies are being shunned - a tailwind for ALC
- Cashflow in Q3 excludes North Cumbria - cash collection commences in 4QFY25
- Hywel Dda goes live in Aug/Sep 2025 - an important go-live for Wales referenceability
- At the end of Q3, Alcidion has $40.2M of contracted and scheduled renewal revenue able to be recognised in FY25 vs FY25 revenue guidance of $37m, underpinning the increased guidance of FY25 EBITDA
I like the trajectory of how ALC has been travelling and these are based on financial numbers, not management promises, so my trust and confidene is very much on the up!
- New contracts, renewals and revenue have been chugging along nicely
- Customer Collections and cash are all trending up nicely and more consistently
- Staff costs have stepped down and are staying down
- Admin and Product costs have been flattish

Discl: Held IRL and in SM